ONWARD Medical NV
F:63E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
ONWARD Medical NV
F:63E
|
NL |
|
J
|
JCU Corp
TSE:4975
|
JP |
|
Ariana Resources PLC
F:4A6
|
UK |
|
Beetaloo Energy Australia Ltd
ASX:BTL
|
AU |
|
Talgo SA
MAD:TLGO
|
ES |
|
B
|
Biprogy Inc
XMUN:NIU
|
JP |
|
V
|
Varengold Bank AG
F:VG8
|
DE |
|
A
|
ALD SA
LSE:0RSP
|
FR |
|
N
|
Nordstrom Inc
XBER:NRD
|
US |
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
IN |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
US |
|
S
|
Sun Pharma Advanced Research Co Ltd
BSE:532872
|
IN |
ONWARD Medical NV
ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage. The company sells its technology to hospitals, doctors, rehabilitation centers, and research partners, and it also works through clinical programs that support future adoption of its devices. It makes money by selling medical devices and related systems, and by moving its therapies through clinical development toward broader medical use. Its business sits between medical device engineering and neurorehabilitation, which means it is not just making hardware but building a treatment approach around that hardware. What makes ONWARD’s business different is that it is trying to turn spinal cord stimulation into a practical therapy for daily life, not just a research tool. Instead of treating symptoms with drugs, it uses targeted electrical signals to help the nervous system regain lost function. That puts the company in a specialized corner of the medtech industry where success depends on clinical evidence, physician adoption, and the ability to make complex neurotechnology usable in real care settings.
ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage.
The company sells its technology to hospitals, doctors, rehabilitation centers, and research partners, and it also works through clinical programs that support future adoption of its devices. It makes money by selling medical devices and related systems, and by moving its therapies through clinical development toward broader medical use. Its business sits between medical device engineering and neurorehabilitation, which means it is not just making hardware but building a treatment approach around that hardware.
What makes ONWARD’s business different is that it is trying to turn spinal cord stimulation into a practical therapy for daily life, not just a research tool. Instead of treating symptoms with drugs, it uses targeted electrical signals to help the nervous system regain lost function. That puts the company in a specialized corner of the medtech industry where success depends on clinical evidence, physician adoption, and the ability to make complex neurotechnology usable in real care settings.
Revenue: ONWARD reported Q1 revenue of EUR 2 million, including EUR 1.3 million of product revenue, as ARC-EX commercialization continued to ramp.
Commercial traction: The company said it supplied 70 ARC-EX systems in the quarter and now has the device in over 100 clinics across the U.S. and Europe.
Home use: Management said first-quarter sales were weighted toward home use, with personal/home units exceeding clinic units for the first time and expected to keep growing.
Pipeline progress: ONWARD enrolled and implanted the first participant in the EMPOWER-BP pivotal trial and has now activated 12 sites.
Funding: The company raised over EUR 40 million in new equity, including EUR 25 million from EQT Life Sciences, extending cash runway into Q1 2028.
Outlook: Management expects more milestones ahead, including Europe home-use sales, ARC-IM mobility work, bladder-related first-in-human use, and the EMPOWER-BP interim readout next spring.
